Abstracts tagged "Systemic sclerosis"

Abstract Number: 0686 • ACR Convergence 2025
Use of a Smartphone App which Incorporates Feedback to Patients to Monitor Systemic Sclerosis-related Digital Ulcers – a Potential New Tool for Remote Clinical Monitoring
Ariane Herrick¹, Paul New², Graham Dinsdale³, Andy Vail², Joanne Manning³, Michael Hughes⁴, Will dixon⁵, Chris Taylor⁵, Mark Dickinson⁵ and Andrea Murray⁶, ¹The University of Manchester, UK, Aberdeen, United Kingdom, ²The University of Manchester, Manchester, United Kingdom, ³Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom, ⁴Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom, ⁵The University of Manchester, Manchester, ⁶University of Manchester, Salford, United Kingdom
Background/Purpose: To facilitate clinical trials we previously developed a smartphone app to allow ‘tracking’ of systemic sclerosis (SSc)-related digital ulcers (DUs) and their associated pain…
Abstract Number: 0882 • ACR Convergence 2025
Serum KL-6 as a Predictive Biomarker for Interstitial Lung Disease Progression and Mortality in Systemic Sclerosis: A Prospective Cohort Study
cristiana Sieiro¹, Jose Ordas Martínez², Sara Calleja Antolín², Juan Garcia Herrero², Javier De la Calle², Miriam Retuerto², Laura Sierra², Elena Bollo de Miguel² and Elvira Díez Álvarez², ¹Univrsity of Manchester, Manchester, United Kingdom, ²Complejo Asistencial Universitario de León, León, Spain
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of morbidity and mortality in systemic sclerosis (SSc). Early detection and continuous monitoring of ILD are…
Abstract Number: 0002 • ACR Convergence 2025
KITE-363: An Autologous Anti-CD19/CD20 CAR-T Product for the Treatment of Autoimmune Rheumatic Diseases
Brian Kim, Christine Lowe, Francisco Flores, Jeremy Margaitis, Alessandro Calo, Stacey Valny, Anna Konecny, Eva Jaghatspanyan, Sean Yoder, Kenneth Ertel, Simone Filosto, Jodi Murakami and David Barrett, Kite, a Gilead Company, Santa Monica, CA
Background/Purpose: B-cell dysregulation is a key factor in the development and progression of autoimmune diseases, and B-cell inhibition has been a cornerstone of treatment for…
Abstract Number: 2496 • ACR Convergence 2025
Comparing Long-term Outcome Across Systemic Sclerosis Subgroups Using a Multi-Organ Disease Progression Score
Philip Yee¹, medha kanitkar², stefano rodolfi³, Voon H. Ong² and Christopher Denton⁴, ¹Division of Medicine, Centre for Rheumatology, University College London, London, England, United Kingdom, ²Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ³University College London, London, United Kingdom, ⁴University College London, UK, London, United Kingdom
Background/Purpose: Evaluating disease modification in systemic sclerosis (SSc) is challenging and requires long term studies. This is especially relevant to limited cutaneous (lc)SSc where severe…
Abstract Number: 2472 • ACR Convergence 2025
Digesting the data: tracking gastro-intestinal manifestations in systemic sclerosis over time
Cosimo Bruni¹, Jasmin Klöti², Aurora Maria Tatu³, Lea Stamm², Rucsandra Dobrota⁴, Muriel Elhai⁵, Mike Becker⁶, Sinziana Muraru⁷, Gesa Sauer⁸, Anna-Maria Hoffmann-Vold⁹, Oliver Distler¹⁰ and Carina Mihai¹¹, ¹University of Zurich, Zurich, Switzerland, ²Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ³Department of Gastroenterology, University Hospital Zurich, University of Zurich, ⁸⁰⁹¹, Switzerland, ⁴Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁵University Hospital zurich, Zürich, Switzerland, ⁶Dept. of Rheumatology, University Hospital Zurich, Zürich, Switzerland, ⁷University of Zurich, University Hospital Zurich, Zürich, Switzerland, ⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, zurich, Switzerland, ⁹Oslo University Hospital, Oslo, Norway, ¹⁰Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ¹¹University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Gastrointestinal (GI) involvement is among the most frequent organ manifestations in systemic sclerosis (SSc), yet the timing of presentation of GI manifestations remains incompletely…
Abstract Number: 1856 • ACR Convergence 2025
Spatial Proteomic-based Phenotyping of Fibroblast Populations and their Microenvironment in Systemic Sclerosis Primary Heart Involvement
Ayla Nadja Stuetz¹, Giacomo de Luca², Alexandru-Emil Matei³, Yi-Nan Li⁴, Veronica Batani², Tim Filla⁵, Aleix Rius Rigau⁶, Bilgesu Safak Tümerdem¹, Cosimo Bruni⁷, Maike Büttner-Herold⁸, Stefania Rizzo⁹, Monica De Gaspari⁹, Markus Eckstein¹⁰, Georg Schett¹¹, Cristina Basso⁹, Jörg Distler¹², Marco Matucci-Cerinic¹³ and Andrea-Hermina Györfi¹⁴, ¹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ²Vita-Salute San Raffaele University. Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy, ³Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, ⁴University Hospital of Düsseldorf, Düsseldorf, Germany, ⁵Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁶Department of Internal Medicine ³, Rheumatology and Clinical Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen. Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Department of Nephropathology, University Hospital Erlangen, Erlangen, Germany, ⁹Cardiovascular Pathology Unit, Department of Cardiac, Thoracic and Vascular Sciences, University and Hospital of Padua, Padua, Italy, ¹⁰Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ¹¹Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹²University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹³University San Raffaele Milano, Milano, Milan, Italy, ¹⁴Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany
Background/Purpose: Primary heart involvement (pHI) is one of the leading causes of death in systemic sclerosis (SSc). However, the cellular and molecular pathomechanisms of SSc-pHI…
Abstract Number: 1568 • ACR Convergence 2025
A Novel Endothelial Cell Profiling Assay to Identify Systemic Sclerosis Patient Characteristics at the Endothelial Cell Level
Eva Hoekstra¹, Rudmer Postma¹, Nils Steinz², Wieke van Oostveen¹, Roel Bijkerk¹, Vincent van Duinen², Rachel Knevel², Tom Huizinga², Anton jan van Zonneveld¹, Jeska de Vries-Bouwstra² and Cynthia Fehres¹, ¹Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Vasculopathy, a hallmark clinical feature in systemic sclerosis (SSc), is a consequence of endothelial cell (EC) damage and dysfunction and might precede tissue fibrosis.…
Abstract Number: 1015 • ACR Convergence 2025
Refining Administrative Algorithms For Accurate Identification of Patients with Systemic Sclerosis In Trinetx Research Network
Gulsen Ozen¹, Michael O'Rorke², Paul Romitti² and Robyn Domsic³, ¹University of Iowa, Carver College of Medicine, Division of Immunology, Coralville, IA, ²University of Iowa College of Public Health, Department of Epidemiology, Iowa City, IA, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Large data-driven medical research is invaluable in answering questions about epidemiology, genetics, therapeutics, and outcomes of rare diseases. Systemic sclerosis (SSc) is rare yet…
Abstract Number: 0957 • ACR Convergence 2025
Multi-Omic Profiling Reveals a Monocyte-Vascular Signature Associated with the Regression of Skin Fibrosis in SSc
Astrid Hofman¹, Pietro Bearzi², Elena Pachera³, Cosimo Bruni⁴, Lumeng Li², Laura Much⁵, Kristina Bürki¹, Mike Becker⁶, Anna-Maria Hoffmann-Vold⁷ and Oliver Distler⁸, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ²Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zürich, Switzerland, ³University Hospital Zurich, Zurich, Switzerland, ⁴University of Zurich, Zurich, Switzerland, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁶Dept. of Rheumatology, University Hospital Zurich, Zürich, Switzerland, ⁷Oslo University Hospital, Oslo, Norway, ⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Regression of skin fibrosis is a feature of the natural history of dcSSc. The molecular mechanisms underlying this resolution remain unclear. This study aims…
Abstract Number: 0685 • ACR Convergence 2025
Targeting Refractory Reflux in Systemic Sclerosis: Early Outcomes following a Novel Intervention
Areeka Memon¹, Monique Hinchcliff² and Amir Masoud³, ¹Yale New Haven Health, New Haven, CT, ²Yale School of Medicine, Westport, CT, ³Hartford Healthcare, hartford
Background/Purpose: Gastrointestinal tract (GIT) symptoms impact up to 90% of individuals with SSc. Hiatal hernia, decreased esophageal contractility, and lower esophageal sphincter tone contribute to…
Abstract Number: 0881 • ACR Convergence 2025
Circulating Monocytes with High Interferon Signature as Precursors to Osteopontin Expressing Lung Macrophages in Patients with Systemic Sclerosis and Progressive Interstitial Lung Disease
Shu-Ju Lin¹, Kimberly Taylor², Shen Yang³, Qinwei Chen⁴, Shehani Alexander¹, Ye Cao⁵, Takanori Sasaki⁵, Deepak Rao⁵, Nunzio Bottini⁶, Francesco Boin³ and Richard Ainsworth⁴, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²UC San Francisco, San Francisco, CA, ³Cedars-Sinai Medical Center, Beverly Hills, CA, ⁴Cedars Sinai Medical Center, Los Angeles, CA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Cedars Sinai Medical Center, Beverly Hills, CA
Background/Purpose: Circulating monocytes with pro-inflammatory and pro-fibrotic phenotype have been implicated in SSc-ILD pathogenesis, but their potential trajectory to mature cell lineage macrophages driving organ-specific…
Abstract Number: 2494 • ACR Convergence 2025
Abatacept Reduces CD319+ (SLAM-F7) Cytotoxic T Cells and Cytokine Production in Systemic Sclerosis
Mikel Gurrea-Rubio¹, Kohei Maeda², Qi Wu³, Phillip L Campbell², Camila I Amarista², Alexander Stinson⁴, Ray Ohara⁵, Laura Cooney⁶, Michael Whitfield⁷, Pei-Suen Tsou⁸, Dinesh Khanna⁸ and David Fox⁹, ¹University of Michigan - Ann Arbor, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, ⁴University of Michigan, Department of Internal Medicine, Division of Rheumatology, Ann Arbor, MI, ⁵University of Michigan, Department of Internal Medicine, Division of Rheumatology, West Bloomfield, MI, ⁶Immune Tolerance Network, Ann Arbor, MI, ⁷Geisel School of Medicine, Lebanon, NH, ⁸University of Michigan, Ann Arbor, MI, ⁹University of Michigan, Dexter, MI
Background/Purpose: While the ASSET clinical trial (placebo-controlled blinded trial of abatacept) in patients with diffuse cutaneous systemic sclerosis (dcSSc) did not meet its primary endpoint…
Abstract Number: 2470 • ACR Convergence 2025
Impaired Myocardial Flow Reserve on 82-Rubidium Positron Emission Tomography in Patients with Systemic Sclerosis
Attila Feher¹, Morgan Emokpae², Bindu Koyi², Ibolya Csecs², Baran Gunes³, Albert Sinusas² and Monique Hinchcliff⁴, ¹Yale University School of Medicine - New Haven, CT, New Haven, CT, ²Yale School of Medicine, New Haven, ³Yale University School of Medicine, Pompton Plains, NJ, ⁴Yale School of Medicine, Westport, CT
Background/Purpose: Cardiovascular death ranks as the second leading cause of mortality related to systemic sclerosis (SSc), with coronary microvascular dysfunction (CMVD) likely contributing to this…
Abstract Number: 1833 • ACR Convergence 2025
DM618: A Novel Anti-IL12p35 Antibody Specifically Inhibiting IL-12 with Therapeutic Potential in a Set of Autoimmune Diseases
Dong ZHANG, Guangan Hu, Xiaodong Jiang, Quanju Zhao, Tainfei Hou, Zhengwang Sun, Mousheng Xu and Nan Bing, D²M Biotherapeutic, Inc, NATICK, MA
Background/Purpose: IL-12, via its p35 subunit, drives Th1-mediated pathology in autoimmune diseases. Genome-wide association studies (GWAS) suggested that IL12A encoding IL12p35 is associated with systemic…
Abstract Number: 1569 • ACR Convergence 2025
Can We Use Patient Reported Outcomes For Home-monitoring in SSc?
Eva Hoekstra¹, Katherine van der Wouden², Queeny Madari¹, Saad Ahmed³, Lianne Kwant¹, Ada Hortensius-Varkevisser¹, Emiel Marges¹, Jacopo Ciaffi⁴, Anne Schouffoer⁵, Tom Huizinga⁶ and Jeska de Vries-Bouwstra⁶, ¹Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, ²Leiden University Medical Center and Amsterdam University Medical Center, Leiden, Zuid-Holland, Netherlands, ³LUMC, Leiden, Netherlands, ⁴IRCCS Istituto Ortopedico Rizzoli, Bologna, Bologna, Italy, ⁵HagaZiekenhuis the Hague, the Hague, Netherlands, ⁶Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Home-monitoring is a suitable strategy to reduce the frequency of hospital visits, and alleviate strain on healthcare resources. However, in systemic sclerosis (SSc) this…

« Previous Page
1
…
3
4
5
6
7
…
56
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].